Polaryx Therapeutics Inc. (PLYX:NASDAQ) closed at $1.75 on October 30, 2026, down 5.91% on the day. It is trading at its 52-week low of $1.75. Over the past year, it lost 95.0%. Polaryx Therapeutics Inc. is part of the Health Care sector.
In 188 trading sessions since February 3, 2026, PLYX closed higher on 79 days (42%). Its best day was March 10, 2026 (+69.60%) and its worst was February 6, 2026 (-44.31%). The stock moved 10% or more in a single session 35 times. It opened at least 5% above the previous day's high 2 times.
Polaryx Therapeutics is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs. Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch a Phase 2 proof-of-concept basket trial which may enhance PLX-200's potential to become the standard of care across multiple LSDs.
Find more stocks like PLYX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.